ABVC BioPharma (NASDAQ:ABVC – Get Free Report) and Evolus (NASDAQ:EOLS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Insider and Institutional Ownership
11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares ABVC BioPharma and Evolus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | N/A | -47.68% | -30.97% |
| Evolus | -10.85% | N/A | -13.00% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
Evolus has a consensus price target of $14.50, indicating a potential upside of 103.08%. Given Evolus’ stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than ABVC BioPharma.
Volatility and Risk
ABVC BioPharma has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Evolus has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Earnings and Valuation
This table compares ABVC BioPharma and Evolus”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ABVC BioPharma | $510,000.00 | 52.86 | -$7.91 million | ($0.30) | -3.37 |
| Evolus | $297.18 million | 1.59 | -$51.64 million | ($0.52) | -13.73 |
ABVC BioPharma has higher earnings, but lower revenue than Evolus. Evolus is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Evolus beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
About Evolus
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
